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vide the orthopaedic surgeon with a simple, inexpensive, cost- 
effective, novel modality for the repair of cartilage lesions. 
Reference 
[1] Pascher et al. Gene transfer to cartilage defects using co- 
agulated bone marrow aspirate. Gene Therapy 11: 133-141, 
2004. 
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STEM CELLS AND SKELETAL TISSUE REGENERATION 
Brian Johnstone 
Adult stem or progenitor cells have now been detected in most tis- 
sues of the body, including those relevant o the musculoskeletal 
system - trabecular bone, bone marrow, periosteum, cartilages, 
synovium, adipose and muscle. The cells of most tissues have 
been shown to have chondrogenic, osteogenic and adipogenic 
differentiation potential, and within bone marrow and muscle, cer- 
tain subfractions with greater differentiation potential are now de- 
scribed. Despite these advances, the relationship between the 
various cells of the different issues is unclear, as is their rela- 
tive importance in the field of regenerative medicine. Stem cell- 
based therapies are still a goal of many in the skeletal biology 
field. However, the early promise has been tempered by the real- 
ization of the complexity of stem cell interactions within implants 
and host tissues that must be understood if we are to provide 
effective regenerative tissues for skeletal pathologies. These is- 
sues will be discussed with examples from our work with human 
tissue-derived cells in attempts to define them and translate the 
findings into cell-based therapies. 
20 
PROTEOMICS IN OSTEOARTHRITIS 
Jeremy Saklatvala 
Proteomics is the study of the total complement of proteins of an 
organism. Generally, proteins of a cell or tissue extract are sepa- 
rated by 2-dimensional gel electrophoresis, detected by sensitive 
staining, excised and identified by mass spectrometry. 
The technique is complementary to transcriptomic analysis. It 
shows the actual level of expression of proteins, and their post- 
translational modifications (i.e. are they appropriately processed, 
glycosylated, phosphorylated and so on). Its limitations are that 
a) it is not possible to resolve the thousands of proteins in a cell by 
current separation methods, b) abundant proteins hinder detec- 
tion of less abundant, c) certain types of protein e.g. membrane 
proteins, very large proteins and those with extreme isoelectric 
points are often not resolved by current gel separation methods, 
and d) quantification is difficult. 
If the aim is to analyse differences between samples, for instance 
between diseased and normal material, or between cells under- 
going different reatments, samples can either be run side by side, 
or various approaches are used in which the two samples are 
mixed and then separated together, after treating them with dif- 
ferent protein dyes, or after differential isotopic labelling. 
We have developed proteomic analysis of articular cartilage, 
firstly, to find out what regulatory molecules it makes, and sec- 
ondly to compare normal with osteoarthritic tissue. Because of 
the impossibility of resolving all the cellular proteins we concen- 
trated on analysing those secreted by chondrocytes in tissue ex- 
plants ex-vivo, and we labelled these metabolically in culture with 
35S-containing methionine and cysteine to be sure we were de- 
tecting chondrocyte proteins. Articular cartilage contains plasma 
proteins and cellular debris such as haemoglobin, which have to 
be washed out of the tissue. If this is not done, analysis of the la- 
belled proteins, which have to be visualisable as silver-stainable 
spots, is prevented. A major technical hurdle was that the proteo- 
glycans, particularly aggrecan, prevented iso-electric focussing 
of other cartilage proteins and had to be removed selectively; this 
was achieved with the cationic detergent cetylpyridirium chloride. 
We were able to produce good maps of the chondrocyte 'secre- 
tome', resolving one to two hundred protein spots and identifying 
forty or so newly synthesised proteins. Differences, particularly 
in collagen II secretion and processing were seen between nor- 
mal and osteoarthritic tissue, and between cartilage of different 
ages. The maps also revealed two potentially important regula- 
tory molecules, activin A and connective tissue growth factor. Ac- 
tivin A was made in striking amounts and its existence in articu- 
lar cartilage has not been previously recognised. Further experi- 
ments suggest it may have important functions regulating matrix 
catabolism in cartilage. 
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EVALUATING SUBCHONDRAL BONE IN 
OSTEOARTHRITIS 
Sharmila Majumdar 
In addition to changes in cartilage that occur in OA, it is sug- 
gested that early changes are seen in the adjoining subchondral 
and trabecular bone. Articular cartilage and subchondral bone 
act in concert with regards to the mechanical oading of the joint 
and its disruption due to injury. The subchondral mineralized zone 
is recognized to play an important role in reducing the axial im- 
pact forces typically encountered uring dynamic joint loading [1] 
and adapts to the mechanical demands during normal and abnor- 
mal joint loading [2-4]. Numerous investigators have measured 
radiographic density of the subchondral bone [2-4]; Eckstein et 
al. have shown that distribution of thickness of subchondral bone 
in the patella show differences between males and females and 
relate to the occurrence of cartilage lesions in the medial com- 
partments, but not in the lateral compartments [5]. In a guinea 
pig menisectomy model, an initial loss of trabecular bone vol- 
ume and thickness was evident, while in the advanced stages, 
there was an enhancement of trabecular volume and thickness 
[6] as demonstrated by micro-CT. In an anterior cruciate liga- 
ment transection induced canine OA model, even after fifty-four 
months of OA, the increase in subchondral bone thickness was 
accompanied by a loss of trabecular bone and thinning [7], also 
demonstrated by micro-CT. Recent advances have made it pos- 
sible to use MR to assess bony changes in addition to soft tissue 
changes. Assessment of bony changes in OA was investigated in 
a guinea pig model [8], and investigators found that the signal in- 
tensity of trabecular bone in MR images accurately reflected the 
degree of osteopenia and trabecular thinning noted around the 
cruciate ligament insertions. The extent of subchondral sclerosis 
and the development of marginal osteophytes were also accu- 
rately represented. Serial observations revealed that MRI can de- 
tect highly significant progression of lytic bone lesions, subchon- 
dral sclerosis, and osteophyte size over periods of six weeks. A 
more recent development in the assessment of trabecular bone 
structure is the use of MRI techniques to obtain non-invasive 
bone biopsies at multiple anatomic sites, quantify trabecular ar- 
chitecture, and derive measures such as the trabecular width, tra- 
becular bone fraction, mean intercept length as well as quantita- 
tive measures of texture such as the fractal characteristics of the 
trabecular bone network [9-12]. Using these techniques, Beuf et 
al. have shown differences between the femoral and tibial bone 
structure in osteoarthritic knees [13], while Lindsey et al. have 
found a relationship between bone structure and articular carti- 
lage morphology in subjects with OA [14]. Blumenkrantz et al. [15] 
have examined bone and cartilage changes longitudinally. They 
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found a large variation in bone and cartilage parameters among 
individual subjects in each group, however, group-specific means 
demonstrate decreasing trends (in bone and cartilage parame- 
ters) in osteoarthritic subjects (especially in mild OA subjects). A 
positive relationship was established between cartilage changes 
and localized bone changes closest to the joint line, while a nega- 
tive relationship was established between cartilage changes and 
global bone changes farthest from the joint line. 
Acknowledgements: This work is supported by NIH grant RO1 
AR-49605. 
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NSAIDs and COXIBs: BENEFIT TO RISK EVALUATION 
Leslie J Crofford 
NSAIDs have long been a mainstay of treatment for patients 
with arthritis, leading to reduced pain and improved function and 
quality of life. The discovery of the cyclooxygenase-2 (COX-2) 
enzyme and pre-clinical data suggesting the potential for re- 
duced gastrointestinal toxicity associated with selective inhibition 
of COX-2 occurred concomitantly with increasing awareness of 
gastrointestinal (GI) toxicity produced by conventional, nonselec- 
tive nonsteroidal anti-inflammatory drugs (NSAIDs). Drugs that 
specifically inhibit COX-2 were developed and early testing sug- 
gested that improved GI safety was possible. However reassur- 
ing the endoscopy trial results, the medical community still de- 
manded proof that these drugs were different from the nons- 
elective NSAIDs. In 1998, the US Food and Drug Administra- 
tion (FDA) requested large clinical safety trials to support pos- 
sible modification of the standard GI warning on NSAIDs. These 
studies included the Vioxx Gastrointestinal Outcome Research 
(VIGOR) trial and the Celecoxib Long-term Arthritis Safety Study 
(CLASS). Although these trials were designed primarily to evalu- 
ate GI endpoints, overall safety data were accumulated that ulti- 
mately served to redirect the clinical discussion toward CV risk. 
Most recently with the withdrawal of rofecoxib and valdecoxib 
from the market in the US and changes in the labeling of non- 
selective drugs, the discussion regarding NSAIDs and COXlBs 
has focused almost exclusively on cardiovascular safety to the ex- 
clusion of possible GI safety and, more importantly, clinical benefit 
to patients with arthritis. Future discussion of this group of drugs 
must focus on a more comprehensive assessment of benefit and 
risk to all organ systems. 
23 
UPDATE ON NSAIDS: ARE THERE ALTERNATIVES? ARE 
THERE ALTERNATIVES TO NSAIDS/COXIBS? 
Sharon L Kolasinski 
Physicians and patients have growing concerns about the safety 
of nonsteroidal anti-inflammatory drugs (NSAIDs) and cyclooxy- 
genase 2 inhibitors (coxibs). The first choice for treatment of 
osteoarthritis (OA) pain is considerably less obvious than just 
a short time ago. The controversies surrounding the use of 
NSAIDs/coxibs do, however, provide us with the opportunity 
to review and rethink our management strategies and to con- 
sider the risks and benefits associated with therapies other than 
NSAI Ds/coxibs. 
Guidance in OA treatment is available from a number of sources 
including the American College of Rheumatology Recommenda- 
tions for the Medical Management of Osteoarthritis of the Hip 
and Knee 2000 Update (Arthritis & Rheumatism 2000;43:1905- 
15) and the reports of the Standing Committee for International 
Clinical Studies Including Therapeutics of the European League 
Against Rheumatism for hip (Ann Rheum Dis 2005;64:669-81) 
and knee (Ann Rheum Dis 2003;62:1145-55) osteoarthritis. Both 
sets of guidelines were developed from a review of evidence from 
the literature, as well as the consensus of experts in the field. Both 
groups emphasize that optimal management requires individual 
assessment of the patient (comorbidities, level of pain, degree of 
disability, extent of structural damage) and the use of nonphar- 
macological therapies (education, exercise, weight reduction, as- 
sistive devices). Topical agents, intraarticular steroid or hyaluronic 
acid injections and surgical procedures including total joint arthro- 
plasty are among recommended options. However, practitioners 
and patients often still depend on oral analgesics as an essential 
component of comprehensive management. 
